Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Immunic Inc (IMUX)

Immunic Inc (IMUX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Immunic Inc 1200 AVENUE SUITE 200 NEW YORK NY 10036 USA

www.immunic-therapeutics.com P: 332-255-9818

Description:

Immunic Inc. is a clinical-stage biopharmaceutical company. It is engaged in developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis and psoriasis. The company's product candidate consists of IMU-838, IMU-935 and IMU-856 which are in clinical stage. Immunic Inc., formerly known as Vital Therapies Inc., is based in San Diego, United States.

Key Statistics

Overview:

Market Capitalization, $K 111,512
Enterprise Value, $K 64,842
Shares Outstanding, K 89,929
Annual Sales, $ 0 K
Annual Net Income, $ -93,610 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -21,570 K
EBIT, $ -99,220 K
EBITDA, $ -99,110 K
60-Month Beta 2.07
% of Insider Shareholders 2.70%
% of Institutional Shareholders 51.82%
Float, K 87,501
% Float 97.30%
Short Volume Ratio 0.67

Growth:

1-Year Return -18.42%
3-Year Return -91.93%
5-Year Return -90.40%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 94.07%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.48 on 02/22/24
Latest Earnings Date 05/09/24
Earnings Per Share ttm -2.11
EPS Growth vs. Prev Qtr 5.88%
EPS Growth vs. Prev Year 70.55%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%
Most Recent Split 1-40 on 04/15/19

IMUX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -157.44%
Return-on-Assets % -117.42%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 1.84
Book Value/Share 0.64
Interest Coverage -4.85
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar